Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lofexidine for Acute Opioid Withdrawal
NCT01863186Phase 3Completed
- Sponsor
- US WorldMeds
- Start
- Jun 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lofexidine in opioid withdrawal syndrome (OWS) (4 arms), sponsored by US WorldMeds. Primary endpoint: Short Opiate Withdrawal Scale of Gossop. Started Jun 2013; status: completed.
02
Drugs
lofexidine
03
Conditions
opioid withdrawal syndrome (OWS)
Beyond the preview
Go deeper on NCT01863186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01863186.